Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Central serous chorioretinopathy treated by a single physician with topical dorzolamid: a pilot study

Poster Details

First Author: B. Heydari IRAN, ISLAMIC REPUBLIC OF

Co Author(s):    G. Yaghoobi                    

Abstract Details

Purpose:

To report central serous chorioretinopathy treated by a single physician with topical dorzolamid: A pilot study.

Setting:

compared basal visual acuity, central macular thickness after intervention

Methods:

These observational case studies included 9 eyes of 9 patients with central serous chorioretinopathy treated by a single physician with topical dorzolamid consecutively over a one month period. The central macular thickness and best-corrected visual acuity were measured and compared with baseline values. All eyes of 9 patients demonstrated subretinal fluid before or during the initiated treatment course. Subretinal fluid was measured and compared with baseline values in this subgroup.

Results:

In all eyes (n = 9) the mean age were 39± 6., best-corrected visual acuity improved at 0.5 months of treatment in 77%(7 cases) and 11.1% (1 case) within one month and 11.1% (1 case) in 2.5 months of follow up, indeed the mean central macular thickness showed improvement from 4.72.± 1.40 to 3.93±9.8 (p=0.2) The subretinal fluid was decreased during of mean 0.7.±0.6 months follow up of treatment; however, central macular thickness, choroidal thickness, and best-corrected visual acuity showed no significant change.

Conclusions:

Topical dorzolamid may improve best-corrected visual acuity and decrease subretinal fluid in patients with central serous chorioretinopathy,This pilot study demonstrates that topical dorzolamid may be effective in treating central serous chorioretinopathy

Financial Disclosure:

NONE

Back to Poster listing